Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin's lymphoma: current status and future prospects.
about
Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with ⁹⁰Y and ¹¹¹In for domestic radioimmunotherapy and radioscintigraphy of non-Hodgkin's lymphomaLanthanides: Applications in Cancer Diagnosis and Therapy.An overview of targeted cancer therapy.Physicochemical Evaluation of Lyophilized Formulation of p-SCN-Bn-DOTA- and p-SCN-Bn-DTPA-rituximab for NHL Radio Immunotherapy.
P2860
Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin's lymphoma: current status and future prospects.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Yttrium ibritumomab tiuxetan i ...... t status and future prospects.
@en
Yttrium ibritumomab tiuxetan i ...... t status and future prospects.
@nl
type
label
Yttrium ibritumomab tiuxetan i ...... t status and future prospects.
@en
Yttrium ibritumomab tiuxetan i ...... t status and future prospects.
@nl
prefLabel
Yttrium ibritumomab tiuxetan i ...... t status and future prospects.
@en
Yttrium ibritumomab tiuxetan i ...... t status and future prospects.
@nl
P2860
P1476
Yttrium ibritumomab tiuxetan i ...... t status and future prospects.
@en
P2093
Samuel A Jacobs
P2860
P304
P577
2007-09-01T00:00:00Z